AMGN
55
-2
SYK
57
-2
HSIC
56
3
QRVO
33
-3
DLTR
31
3
MNST
52
2
NWL
32
-3
BBY
59
7
TGNA
51
3
AIG
51
-2
HPE
53
2
PSX
42
3
DOV
63
-6
GOOGL
53
2
NEE
52
-2
ED
53
-5
PLD
51
-5
EMN
70
-2
HPQ
62
2
XOM
48
3
AMGN
55
-2
SYK
57
-2
HSIC
56
3
QRVO
33
-3
DLTR
31
3
MNST
52
2
NWL
32
-3
BBY
59
7
TGNA
51
3
AIG
51
-2
HPE
53
2
PSX
42
3
DOV
63
-6
GOOGL
53
2
NEE
52
-2
ED
53
-5
PLD
51
-5
EMN
70
-2
HPQ
62
2
XOM
48
3
Financhill
Back

ARS Pharmaceuticals Quote, Financials, Valuation and Earnings

The Next Tech Giant in Your Pocket?

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
35

SPRY
ARS Pharmaceuticals

Last Price:
14.87
Seasonality Move:
-2.91%

7 Day Trial

ALL ACCESS PASS

$ 7

"EarnPhone": The Investment Hidden in Plain Sight

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

ARS Pharmaceuticals Price Quote

$14.87
+0.82 (+5.84%)
(Updated: September 19, 2024 at 6:55 PM ET)

ARS Pharmaceuticals Key Stats

Sell
35
ARS Pharmaceuticals (SPRY) is a Sell
Day range:
$13.10 - $14.32
52-week range:
$2.55 - $16.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
6.33%
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
88.84%
Market cap:
$1.4B
Revenue:
$30K
EPS:
$-0.47

How Much Does ARS Pharmaceuticals Make?

Data Unavailable

Is ARS Pharmaceuticals Growing As A Company?

  • What Is ARS Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 49%
  • What Is ARS Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

ARS Pharmaceuticals Stock Price Performance

What Is ARS Pharmaceuticals 52-Week High & Low?

ARS Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy ARS Pharmaceuticals?

Is ARS Pharmaceuticals Cash Flow Positive?

  • What Is SPRY Cash Flow From Operations?
    Cash flow from operations (TTM) is -$44.2M
  • What Is ARS Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $3.5M
  • What Is ARS Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$41.8M

ARS Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    SPRY return on invested capital is -19.4%
  • What Is ARS Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -18.84%
  • What Is SPRY Return On Equity?
    ROE is a measure of profitability and is -19.4%

ARS Pharmaceuticals Earnings Date & Stock Price

ARS Pharmaceuticals Competitors

  • Who Are ARS Pharmaceuticals's Competitors?
    Below is a list of companies who compete with ARS Pharmaceuticals or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Aquestive Therapeutics Inc (AQST)
    • CEL-SCI Corp (CVM)
    • IGC Pharma Inc (IGC)
    • NovaBay Pharmaceuticals Inc (NBY)

ARS Pharmaceuticals Dividend Yield

ARS Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -13.04%
Revenue: 4900% -25%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 24.33
Upside from Last Price: 73.19%

Major Shareholders

  • How many SPRY shares are owned by institutional investors?
    88.7M SPRY shares are owned by institutional investors
  • How many SPRY shares are owned by insiders?
    8.3M SPRY shares are owned by insiders